These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37862551)

  • 1. Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Ajmera V; Tesfai K; Sandoval E; Lopez S; Cervantes V; Madamba E; Bettencourt R; Manousou P; Richards L; Loomba R
    Hepatology; 2024 May; 79(5):1098-1106. PubMed ID: 37862551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
    Udompap P; Therneau TM; Canning RE; Benson JT; Allen AM
    Hepatology; 2023 Mar; 77(3):931-941. PubMed ID: 35989502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
    Arai T; Takahashi H; Seko Y; Toyoda H; Hayashi H; Yamaguchi K; Iwaki M; Yoneda M; Shima T; Fujii H; Morishita A; Kawata K; Tomita K; Kawanaka M; Yoshida Y; Ikegami T; Notsumata K; Oeda S; Atsukawa M; Kamada Y; Sumida Y; Fukushima H; Miyoshi E; Aishima S; Okanoue T; Itoh Y; Nakajima A;
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):789-797.e8. PubMed ID: 38048934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
    Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
    JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
    Bridi L; Agrawal S; Tesfai K; Madamba E; Bettencourt R; Richards LM; Khera AV; Loomba R; Ajmera V
    Aliment Pharmacol Ther; 2024 Aug; 60(3):369-377. PubMed ID: 38825972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
    McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
    BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
    Vieira Barbosa J; Lai M
    Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
    J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.